Elvitegravir / Cobicistat

Buspirone

Evaluate risk/benefit ratio.

No pharmaceutical opinion available for this interaction.

Mechanism

Elvitegravir / Cobicistat can inhibit the metabolism (CYP 3A4) and increase the plasma concentration of Buspirone.

Elvitegravir / Cobicistat

Pharmacodynamic effects

Recommendations

Alternative solution(s)

Buspirone

Pharmacodynamic effects

Increased risk of CNS toxicity.

Risk of prolonged sedation and respiratory depression.

Recommendations

Use with caution the lowest effective dose and adjust according to clinical response and tolerance.

Monitor closely for adverse effects.

Or choose an alternative.

In patients already being treated with this combination and tolerating it, if deemed appropriate, keep actual treatment and exercise close monitoring of adverse effects and clinical effectiveness.

Alternative solution(s)

Lorazepam (Ativan), temazepam (Restoril), oxazepam (Serax).

Monitor

Buspirone toxicity: impaired psychomotor performance, nausea, vomiting, dizziness, drowsiness, miosis, etc.

Tests

Pharmacokinetic parameters

Comment

Reference
  • 3281
    Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya), Gilead, Ontario, Canada, 6 août 2021.
  • 2570
    Elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild), Gilead, Ontario, Canada, 17 septembre 2018.